Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 53Completed 46Unknown 32Terminated 14Active not recruiting 12Withdrawn 6Not yet recruiting 5Suspended 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Malignancies 1Advance Solid Tumors 1

Interventions

Specimen Handling 15Biopsy 9Cyclophosphamide 8Magnetic Resonance Spectroscopy 7venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Carboplatin 3zanubrutinib 2prednylidene 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Vincristine 2Rituximab 2Radiotherapy, Intensity-Modulated 2Protein Subunit Vaccines 2Prednisone 2Nivolumab 2Melphalan 2Injections 2Gemcitabine 2E 7107 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Injections × Clear all
NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 1 Suspended
16 enrolled
Other solid neoplasm

Advance Solid Tumors

NCT06388902 2025-11-21

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Suspended
120 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡